San Francisco startup Framework Therapeutics is also working on an oral, when-daily GLP-1 drug termed GSBR-1290—the drug surpassed Wall Avenue’s anticipations in June any time a mid-phase research showed ordinary weight loss of around 6% and it options to begin An additional mid-stage trial toward the end of the yr—that founder and CEO Raymon… Read More